Myovant Sciences Ltd.
(NYSE : MYOV)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
2.48%200.451.2%$531.87m
GILDGilead Sciences, Inc.
3.46%75.300.9%$475.69m
BIIBBiogen Inc.
1.64%333.811.3%$390.98m
CELGCelgene Corporation
2.07%83.521.2%$346.19m
ILMNIllumina, Inc.
2.14%320.103.5%$304.01m
REGNRegeneron Pharmaceuticals, Inc.
4.49%394.502.6%$238.74m
ALXNAlexion Pharmaceuticals, Inc.
4.70%127.202.0%$225.19m
VRTXVertex Pharmaceuticals Incorporated
3.24%183.401.9%$217.30m
SRPTSarepta Therapeutics, Inc.
4.53%137.2916.4%$178.87m
AAgilent Technologies, Inc.
2.26%67.111.5%$161.03m
BMRNBioMarin Pharmaceutical Inc.
4.94%104.364.4%$142.05m
LGNDLigand Pharmaceuticals Incorporated
6.36%212.8023.3%$122.70m
VKTXViking Therapeutics, Inc.
7.47%15.260.9%$120.40m
NKTRNektar Therapeutics
2.77%50.445.6%$112.07m
EXASExact Sciences Corporation
1.32%66.6425.3%$104.38m

Company Profile

Myovant Sciences, Inc. is a clinical-stage biopharmaceutical company. It focuses on developing and commercializing therapies for the treatment of women's health and endocrine diseases. The company's product includes relugolix, which is an oral, once-daily and small molecule that acts as a GnRH receptor antagonist. It also develops MVT-602 a kisspeptin agonist for the treatment of female infertility. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.